NCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05554328 2026-04-13
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05887609 2026-04-13
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
Phase 2 Recruiting
NCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT06580314 2026-03-24
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT07371104 2026-03-05
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Daewoong Pharmaceutical Co. LTD.
Phase 1 Recruiting
NCT05932862 2025-09-05
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Phase 1 Recruiting
NCT07069335 2025-07-16
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Boryung Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT06377267 2024-05-09
STROBE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT05255471 2023-03-24
MITO 35B
National Cancer Institute, Naples
Phase 3 Recruiting